Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964238 | 0.81 | ALOX15B (0.49) | NOTUMCYP19A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6609392 | 0.80 | MAPKAPK2 (0.43) | NOTUMCYP19A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6177595 | 0.80 | MKNK1 (0.43) | SMN1; SMN2LMNACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL23196722 | 0.80 | CYP3A4 (0.44) | NOTUMSMN1; SMN2GAACYP19A1HCAR1 | |
| SCHEMBL10594306 | 0.80 | ENPP2 (0.41) | LMNACYP19A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL353826 | 0.79 | CYP3A4 (0.50) | SMN1; SMN2GAACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9802365 | 0.79 | MAPK9 (0.37) | SMN1; SMN2GAACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL27577364 | 0.78 | CYP3A4 (0.42) | NOTUMSMN1; SMN2LMNACYP19A1HCAR1 | |
| SCHEMBL2269279 | 0.78 | CYP3A4 (0.49) | SMN1; SMN2GAACYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9763105 | 0.77 | KEAP1 (0.46) | NOTUMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| CN-102395567-A | Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity | EXELIXIS INC | 2012-03-28 | — | — | CN | disclosed |
| EP-1373217-A1 | 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS | Beiersdorf AG (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076951-A1 | 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS | BEIERSDORF AG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | NOTUM 4291/4885TP53 149/4885THRB 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.